DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more
DNA Link Inc (127120) - Net Assets
Latest net assets as of September 2025: ₩46.15 Billion KRW
Based on the latest financial reports, DNA Link Inc (127120) has net assets worth ₩46.15 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩94.71 Billion) and total liabilities (₩48.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩46.15 Billion |
| % of Total Assets | 48.72% |
| Annual Growth Rate | 6.15% |
| 5-Year Change | -35.33% |
| 10-Year Change | 123.45% |
| Growth Volatility | 341.98 |
DNA Link Inc - Net Assets Trend (2011–2024)
This chart illustrates how DNA Link Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DNA Link Inc (2011–2024)
The table below shows the annual net assets of DNA Link Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩25.03 Billion | -4.75% |
| 2023-12-31 | ₩26.28 Billion | -5.78% |
| 2022-12-31 | ₩27.89 Billion | -14.89% |
| 2021-12-31 | ₩32.77 Billion | -15.33% |
| 2020-12-31 | ₩38.70 Billion | +300.56% |
| 2019-12-31 | ₩9.66 Billion | -50.71% |
| 2018-12-31 | ₩19.60 Billion | -17.13% |
| 2017-12-31 | ₩23.66 Billion | +1203.01% |
| 2016-12-31 | ₩1.82 Billion | -83.79% |
| 2015-12-31 | ₩11.20 Billion | +44.87% |
| 2014-12-31 | ₩7.73 Billion | -56.32% |
| 2012-12-31 | ₩17.70 Billion | +53.68% |
| 2011-12-31 | ₩11.52 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DNA Link Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7902312922000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩11.24 Billion | 44.91% |
| Other Components | ₩100.08 Billion | 399.83% |
| Total Equity | ₩25.03 Billion | 100.00% |
DNA Link Inc Competitors by Market Cap
The table below lists competitors of DNA Link Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shaily Engineering Plastics Limited
NSE:SHAILY
|
$538.66 Million |
|
Henan Thinker Automation
SHG:603508
|
$538.70 Million |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
$538.82 Million |
|
KATITAS CO., Ltd.
PINK:KTITF
|
$538.93 Million |
|
Winner Information Technology Co Inc
SHE:300609
|
$538.34 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
$538.29 Million |
|
Scientech Corp
TW:3583
|
$537.99 Million |
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
$537.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DNA Link Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,277,552,340 to 25,029,674,160, a change of -1,247,878,180 (-4.7%).
- Net loss of 10,801,688,730 reduced equity.
- Share repurchases of 8,775,050,830 reduced equity.
- New share issuances of 8,775,050,830 increased equity.
- Other factors increased equity by 9,553,810,550.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.80 Billion | -43.16% |
| Share Repurchases | ₩8.78 Billion | -35.06% |
| Share Issuances | ₩8.78 Billion | +35.06% |
| Other Changes | ₩9.55 Billion | +38.17% |
| Total Change | ₩- | -4.75% |
Book Value vs Market Value Analysis
This analysis compares DNA Link Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 35.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 147.25x to 35.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩271.99 | ₩40050.00 | x |
| 2017-12-31 | ₩2072.21 | ₩40050.00 | x |
| 2018-12-31 | ₩1717.22 | ₩40050.00 | x |
| 2019-12-31 | ₩791.89 | ₩40050.00 | x |
| 2020-12-31 | ₩2360.94 | ₩40050.00 | x |
| 2021-12-31 | ₩1999.03 | ₩40050.00 | x |
| 2022-12-31 | ₩1631.61 | ₩40050.00 | x |
| 2023-12-31 | ₩1537.27 | ₩40050.00 | x |
| 2024-12-31 | ₩1113.23 | ₩40050.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DNA Link Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -67.90%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 2.17x
- Recent ROE (-43.16%) is above the historical average (-88.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -57.67% | -51.06% | 0.43x | 2.65x | ₩-5.23 Billion |
| 2015 | -80.83% | -96.12% | 0.29x | 2.92x | ₩-10.17 Billion |
| 2016 | -540.40% | -85.44% | 0.44x | 14.24x | ₩-9.99 Billion |
| 2017 | 1.43% | 2.33% | 0.58x | 1.06x | ₩-2.03 Billion |
| 2018 | -19.14% | -25.23% | 0.42x | 1.79x | ₩-5.71 Billion |
| 2019 | -135.76% | -84.24% | 0.60x | 2.68x | ₩-14.08 Billion |
| 2020 | -33.76% | -85.48% | 0.29x | 1.36x | ₩-16.94 Billion |
| 2021 | -15.56% | -22.18% | 0.56x | 1.25x | ₩-8.38 Billion |
| 2022 | -27.90% | -45.82% | 0.39x | 1.56x | ₩-10.57 Billion |
| 2023 | -21.30% | -25.50% | 0.57x | 1.47x | ₩-8.22 Billion |
| 2024 | -43.16% | -67.90% | 0.29x | 2.17x | ₩-13.30 Billion |
Industry Comparison
This section compares DNA Link Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DNA Link Inc (127120) | ₩46.15 Billion | -57.67% | 1.05x | $538.59 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |